Dyno Therapeutics

Come join us at Dyno Therapeutics! 🚀 🌟Rebecca Servais is hiring a Sr. Manager/Manager - Laboratory Operations🌟 In this role you will be responsible for leading effective and efficient laboratory operations, including stewarding laboratory resources, ensuring compliance with safety and regulatory standards, and facilitating a productive research environment to support Dyno’s R&D goals and projects. Are you or someone you know interested? Apply or send me a message! #hiring #dynotherapeutics #AAV #bostonbiotech #biotechjobs #bostonstartups #laboratoryoperations

It was a pleasure sharing with Benchling how efficient lab software supports us in our mission of using AI to engineer effective delivery of gene therapies to every cell, for every patient! Check out this video where our founder Eric Kelsic talks about this:

This month, we recognize the LGBTQIA+ community's resilience and achievements, as well as reflect on ways we can continue to uphold inclusivity and celebrate all identities at Dyno. This means creating a workplace where every individual, regardless of their sexual orientation or gender identity, feels valued, respected, safe, and empowered to bring their true selves to work. To commemorate this month, each week at Dyno will be themed to highlight the LGBTQIA+ movement and support the community. The themes include: 🏳️🌈 Celebrating Pride Month! 🏳️🌈 History of Pride Month and LGBTQIA+ Movement 🏳️🌈 Supporting the LGBTQIA+ community 🏳️🌈 Resources for LGBTQIA+ employees We are continuing to support each other and create a workplace where everyone feels valued and respected. Happy Pride!

Dyno is back from our tour of conferences! We covered a lot of ground at #ASGCT2024 #SynBioBeta2024 and #ARVO24, presenting on our brain and eye capsids, the importance of AI translatability, and how AI-driven protein design will dramatically expand the impact of gene therapies.

Join us today at our #ASGCT24 oral abstract presentation to learn more about how Dyno is applying AI, including our Low-shot Efficient Accelerated Performance (LEAP) technology, to speed up the discovery of AAV capsids for neuronal delivery. ►Presenter: Mugdha Deshpande ►Date and time: Friday May 10, 2024 5:00pm - 5:15PM EDT ►Location: Baltimore Convention Center, Ballroom 4  ►Abstract number: #301

We are excited to announce an AI-focused collaboration with NVIDIA! Teaming up with the world’s leading high-performance computing company and building within NVIDIA's BioNeMo will accelerate Dyno's AI-powered sequence design and brings us all closer to helping patients with transformative new medicines. Learn more on the Dyno website: https://lnkd.in/d3XvdhAJ

TODAY: Join Dyno CEO and founder Eric Kelsic at this year’s ASGCT Symposium to discover our latest breakthroughs in algorithmic design, and learn how Dyno’s Machine Learning methods are ushering in the future of gene delivery. #ASGCT2024 #ASGCT24 ►AAV Capsid Design in the Era of Artificial Intelligence ►Presenter:  Eric Kelsic, Ph.D., Co-founder and CEO, Dyno Therapeutics ►Date and time: Thursday May 9th 12:15 to 13:15 EDT ►Location: Baltimore Convention Center, Room 309-310

Dyno will be on the main stage at #SynBioBeta2024 today at 11am for a talk on how AI-driven protein design can dramatically expand the scope and impact of gene therapies, bringing life-changing treatments within reach for many more patients. We’ll see you there! ► AI-designed capsids: Powering a new age of genetic medicine  ►Date and time: May 8th, 2024, 11:00-11:45 PDT ►Location: San Jose Convention Center, Main Stage - Grand Ballroom 220A Gene therapy is on the brink of offering potentially lifelong cures for patients with currently incurable diseases. However, a key obstacle is the precise and efficient delivery of therapeutic genes to target cells and organs. By leveraging over a decade of research on generative AI and in vivo experiments, we can redesign AAV capsids and modify highly complex protein assembly at scale to enable precise and efficient gene delivery. These synthetic capsids are vastly different from what nature could ever create: much better at targeting specific organs and also less prone to neutralization by pre-existing immunity. As a result, they have the potential to dramatically expand the scope and impact of gene therapies, bringing life-changing treatments within reach for many more patients. Join this talk and hear about the leading edge of AI-driven protein design with a clear case of real-world validation and impact.

Dyno is in Seattle this week for the annual meeting of the Association for Research in Vision and Ophthalmology 👁🧬 We’ll be presenting the latest data from our field-leading Dyno eCap 1 AAV vector for gene delivery to the eye. See you there! #ARVO2024